Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher Sellers

Internal Medicine Chapel Hill, NC Medical Doctor

NPI 1205060712 CMS profile 1280638

101 Manning Dr, Cb # 7030, Chapel Hill, NC 27599

Open in the dashboard

General payments

$7,280

246 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$251,915 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Christopher Sellers of Chapel Hill, NC is reported in the CMS Open Payments database as having received $7,280 across 246 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $251,915 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $933 4
2024 General $338 18
2023 General $780 43
2022 General $826 44
2021 General $3,041 58
2020 General $635 35
2019 General $726 44

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Sellers
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Christopher Sellers were reported at $933. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Christopher Sellers Internal Medicine median Middle half National median
2019 $726 $159 $48–$570 $163
2020 $635 $119 $33–$402 $114
2021 $3,041 $135 $37–$521 $132
2022 $826 $141 $42–$496 $149
2023 $780 $149 $45–$519 $160
2024 $338 $154 $47–$537 $164
2025 $933 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Theratechnologies Inc. $2,066 5 payments
  2. ViiV Healthcare Company $1,620 94 payments
  3. Gilead Sciences, Inc. $1,436 80 payments
  4. La Jolla Pharmaceutical Company $824 2 payments
  5. Janssen Biotech, Inc. $720 42 payments
  6. Janssen Products, LP $317 5 payments
  7. Merck Sharp & Dohme Corporation $182 12 payments
  8. Napo Pharmaceuticals Inc $92 5 payments
  9. AbbVie, Inc. $23 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,181 235 payments
  2. Consulting Fee $2,728 3 payments
  3. Education $317 5 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $54 3 payments
Products named General payments · program years 2019–2025
  1. DOVATO $1,171 75 payments
  2. SYMTUZA $948 41 payments
  3. CABENUVA Hiv $183 7 payments
  4. PIFELTRO $167 11 payments
  5. DELSTRIGO $167 11 payments
  6. ISENTRESS $121 9 payments
  7. CABENUVA Hiv $110 2 payments
  8. Mytesi $92 5 payments
  9. APRETUDE $87 1 payment
  10. PREZCOBIX $81 5 payments
  11. Other $414 26 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

540

Median for Infectious Disease: 268

Drug cost

$846,493

Median for Infectious Disease: $217,595

Branded share of claims

62.8%

Median for Infectious Disease: 45.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 82 $329,708
Symtuza Darunavir/Cob/Emtri/Tenof Alaf Brand 25 $116,138
Genvoya Elviteg/Cob/Emtri/Tenof Alafen Brand 20 $86,691
Tivicay Dolutegravir Sodium Brand 37 $85,229
Descovy Emtricitabine/Tenofov Alafenam Brand 37 $81,026
Dovato Dolutegravir Sodium/Lamivudine Brand 17 $48,666
Odefsey Emtricitab/Rilpiviri/Tenof Ala Brand 11 $38,738
Mytesi Crofelemer Brand 12 $27,953
Isentress Raltegravir Potassium Brand 13 $25,539
Ceftriaxone Ceftriaxone Sodium Brand 12 $3,326

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,546 Part D prescribers listed as Infectious Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$7,989

Medicare's payments for the services billed

Medicare patients

43

Average age 60

Services billed

154

14 women, 29 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 37%
Chronic kidney disease 37%
Ischemic heart disease 35%
Depression 35%
Arthritis 33%
COPD 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DOVATO
  • ViiV Healthcare Company $105
$105 17 —
APRETUDE
  • ViiV Healthcare Company $47
$47 — —
PIFELTRO
  • Merck Sharp & Dohme Corporation $10
$10 — —
DELSTRIGO
  • Merck Sharp & Dohme Corporation $10
$10 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

246 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record